• Sign up to our Free Newsletter
  • Contact Us
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login/ Register
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Month: September 2022

Editor's Choice

A microbiome therapeutic is closer than ever to market authorization in the US. What does it mean for the industry?

September 28, 2022 Kristina Campbell

Ferring Pharmaceuticals, Inc. has edged ahead in the race to bring the first microbiome-based drug to market in the United States, with its product REBYOTA receiving the thumbs up from the FDA’s Vaccines and Related […]

Editor's Choice

Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660

September 23, 2022 Microbiome Times

Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) issued a positive vote for RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential […]

Finance

Great learning experience to watch microbiome startups pitch

September 14, 2022 Microbiome Times

The Microbiome Signature Project arranges a Pitch Day on 27 September in Malmö, Sweden as the final event of the three-year-long project. It is a unique event to showcase startups in Medicon Valley within the […]

Pharma & Human Health

Pherecydes Pharma Announces Registration of Its in Vitro Diagnostic Test in Accordance With EC Directives

September 13, 2022 Microbiome Times

Pherecydes Pharma (FR0011651694 – ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announces the registration of its phagogram as an in vitro diagnostic test (“Phagogram 1.5”) […]

Editor's Choice

Stanford researchers construct most complex, complete synthetic microbiome

September 9, 2022 Microbiome Times

Key studies in the last decade have shown that the gut microbiome, the collection of hundreds of bacterial species that live in the human digestive system, influences neural development, response to cancer immunotherapies, and other […]

Finance

Gensaic enters into collaboration to develop phage-derived gene therapies for CNS

September 5, 2022 Microbiome Times

Gensaic, a company that seeks to reimagine gene therapy, announced today that it has entered into a strategic collaboration agreement with Ovid Therapeutics. Under the terms of the collaboration, Gensaic will exclusively develop phage-derived gene […]

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • “Probiotics” Green-lit for market-usage by French Authorities
    January 25, 2023
  • Microbiome Drug Development: 2022 in Review
    December 30, 2022
  • Exclusive Interview with Ken Blount, VP Microbiome Research at Ferring Pharmaceuticals
    December 22, 2022
  • FDA Approves First Fecal Microbiota Product
    December 1, 2022
  • Proge Farm claims Europe’s first regulatory approval for a microbiome-based therapeutic
    November 29, 2022
sign up

Sign up to the Microbiome Times newsletter